Miravant Medical Technologies
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Miravant Medical Technologies
The Swiss drug maker will initiate a "mass dismissal" and return rights to its lead drug candidate after the US FDA alerted the company to NDA deficiencies.
Amylyx is funding research at the Sunnybrook Research Institute to investigate Bax and Bak inhibition in neurodegenerative disease. Repertoire looks into HPV+ cancer with Memorial Sloan Kettering.
French AI-driven drug design firm will employ multiple technology platforms in latest tie-ups. Apellis looks to augment Empaveli-led portfolio in C3 complement R&D alliance with Affilogic.
Italfarmaco’s HDAC inhibitor helped ambulatory Duchenne muscular dystrophy patients climb stairs faster than non-treated boys while Capricor’s cell therapy improved upper limb function in non-ambulatory patients.
- Radiopharmaceuticals, Contrast Agents
Surgical Equipment & Devices
- Minimally or Less Invasive
- Surgical Equipment & Devices
- Other Names / Subsidiaries
- Miravant Pharmaceuticals Inc